Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Eculizumab for High-risk Transplant-associated Thrombotic Microangiopathy.

NCT07707687 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT07707687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07707687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Eculizumab for High-risk Transplant-associated Thrombotic Microangiopathy.
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 2
Overall status
Recruiting
Start date
July 10, 2026
Completion date
July 10, 2028
Enrollment
24 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

transplant-associated thrombotic microangiopathy (ta-tma)